Terumo Acquires 5% of Fuji Pharma To Grow Drug/Device Combo Product Business
This article was originally published in PharmAsia News
Executive SummaryTOKYO - Japanese device maker Terumo Corp. reached an agreement to purchase 5 percent of Fuji Pharma common shares for jointly developing a drug and device combination product business in Japan - the first such convergence undertaking in a country where the government in the past administered the pharmaceutical and medical device markets almost separately
You may also be interested in...
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).